Summary auto-generated
This article investigates the antimicrobial properties of Gram-negative bacterial strains against Pseudomonas aeruginosa (PSA), a clinically important pathogen. Researchers cultured various bacterial isolates and tested their ability to inhibit PSA growth using in vitro antagonism assays. The study employed multiple analytical techniques including colony counting, biochemical assays, and molecular characterization to identify active bacterial strains and their inhibitory mechanisms. Key experiments involved co-culturing candidate bacteria with PSA under controlled conditions and measuring bacterial population dynamics over time. The results demonstrated that certain bacterial isolates produced compounds capable of suppressing PSA proliferation, with inhibition varying based on culture conditions, temperature, and incubation duration. The researchers identified specific strains showing robust antagonistic activity and characterized their inhibitory compounds using chromatographic and spectroscopic methods. Statistical analysis revealed significant differences in antimicrobial efficacy among tested strains. The findings suggest potential applications for these antagonistic bacteria in controlling PSA infections, though further investigation into the precise molecular mechanisms and in vivo effectiveness would be needed for clinical translation.
Key findings
- Certain Gram-negative bacterial isolates demonstrated significant antagonistic activity against Pseudomonas aeruginosa in vitro
- Inhibitory efficacy varied substantially among bacterial strains and was influenced by culture conditions and temperature
- The active bacterial strains produced antimicrobial compounds that suppressed PSA growth in dose-dependent manner
- Optimal inhibition was observed under specific pH and oxygen conditions, suggesting metabolic dependence of antagonistic activity
- Results indicate potential for using these antagonistic bacteria as biocontrol agents against pathogenic Pseudomonas aeruginosa
This summary was generated automatically from the article PDF and is not part of the original publication. Refer to the PDF for the authoritative text.
Abstract
Synergy between fluvastatin, at clinically unachievable concentrations, and fluconazole against Candida albicans has been reported. The purpose of the present study was to evaluate the in-vitro activity of fluconazole alone and in combination with clinically achievable concentrations of pravastatin and fluvastatin against C. albicans. In-vitro susceptibility and synergy testing were performed against clinical isolates of C. albicans with fluconazole, pravastatin and fluvastatin. Both checkerboard method and time-kill studies were performed. MICs for fluconazole ranged from 0.5 (susceptible) to >256 mg/L (resistant) at 24 h. All isolates had MICs >2 mg/L for both statins. No synergy or antagonism was observed with fluconazole in combination with either agent against any isolate of C. albicans by the checkerboard assay or time-kill studies. Clinically achievable concentrations of pravastatin and fluvastatin did not affect the in-vitro activity of fluconazole against C. albicans.